Jazz On Track With Q4 EU Filing for Leukemia Treatment Vyxeos

 
• By Neena Brizmohun

As European regulators this week consider whether to fast-track the eventual regulatory review of Jazz Pharmaceuticals’ treatment for acute myeloid leukemia, the company says it is on track to file for EU regulatory approval this year.

Sumbit
Jazz plans to submit Vyxeos for EU marketing approval this year • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards